Browse by author
Lookup NU author(s): Dr Pasquale RescignoORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2024 Informa UK Limited, trading as Taylor & Francis Group.Aims: Anemia, mean corpuscular volume and red cell distribution width may have some effects on survival outcomes of metastatic renal cell carcinoma (mRCC) patients and are incorporated in a red blood cell (RBC)-based score. Its validity in prognostication of mRCC patients treated with second-line nivolumab was assessed. Patients and methods: Retrospective analysis using Meet-URO-15 cohort of mRCC patients receiving nivolumab in the second-line setting or beyond. Outcomes were overall survival (OS) and progression-free survival (PFS). Results: A total of 390 patients were included. Significant differences in OS and PFS between RBC-based score groups, with group 1 (2 or 3 of the RBC-related prognostic factors) having longer OS (median 29.5 months, 95% CI: 23.1–35.9, versus 11.5 months, 95% CI: 8.5–22.6; p < 0.001) and PFS (7.5 months, 95% CI: 5.5–10.2, versus 4.2 months, 95% CI: 3.3–5.9; p = 0.040) than those in group 0 (0 or 1 RBC-related prognostic factors). Belonging to group 1 independently predicted OS (hazard ratio: 0.65, 95% CI: 0.50–0.85; p = 0.002) but not PFS (hazard ratio: 0.89, 95% CI: 0.70–1.14, p = 0.370) or disease response (OR 0.68, 95% CI: 0.41–1.10; p = 0.118) at multivariable analysis. Conclusion: RBC-based group scores independently predicted OS in mRCC patients treated with nivolumab.
Author(s): Anpalakhan S, Banna GL, Rebuzzi SE, Fornarini G, Maruzzo M, Zucali PA, Catalano F, Antonj L, Tudini M, Fratino L, Malgeri A, Rescigno P, Signori A, Acunzo A, Silini EM, Mazzaschi G, Buti S
Publication type: Article
Publication status: Published
Journal: Immunotherapy
Year: 2024
Volume: 16
Issue: 14-15
Pages: 963-973
Online publication date: 06/08/2024
Acceptance date: 17/07/2024
ISSN (print): 1750-743X
ISSN (electronic): 1750-7448
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/1750743X.2024.2382666
DOI: 10.1080/1750743X.2024.2382666
PubMed id: 39105621
Altmetrics provided by Altmetric
